Therapy of Graves' ophthalmopathy: A novel application of somatostatin analogues

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 9, 2001, Pages 1361-1365

  Diez J J ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Graves' ophthalmopathy; Somatostatin analogues

Indexed keywords

ANGIOPEPTIN; AUTOANTIBODY; AZATHIOPRINE; CD4 ANTIGEN; CD8 ANTIGEN; CORTICOSTEROID; CYCLIC AMP; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; FORSKOLIN; GLUCOCORTICOID; GLYCOSAMINOGLYCAN; IMMUNOGLOBULIN; INTERCELLULAR ADHESION MOLECULE 1; IODINE 123; OCTREOTIDE; OCTREOTIDE[3 TYROSINE]; PENTETREOTIDE IN 111; PROTEIN BCL 2; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; THYROTROPIN RECEPTOR;

ANTIGEN RECOGNITION; CLINICAL TRIAL; DECOMPRESSION SURGERY; DOSE RESPONSE; DRUG MECHANISM; EDITORIAL; ENDOCRINE OPHTHALMOPATHY; EXOPHTHALMOS; EYE SURGERY; FIBROBLAST CULTURE; GASTROINTESTINAL SYMPTOM; GRAVES DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAOCULAR PRESSURE; ORBIT; PATHOGENESIS; PLASMAPHERESIS; RADIOTHERAPY; SCINTIGRAPHY; SLOW RELEASE FORMULATION; T LYMPHOCYTE SUBPOPULATION;

CLINICAL TRIALS; GRAVES DISEASE; HORMONES; HUMANS; SOMATOSTATIN;

EID: 0034844412     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.9.1361     Document Type: Editorial

References (42)

1. Pathogenesis of Graves' ophthalmopathy
2. Graves' ophthalmopathy: Current concepts regarding pathogenesis and management
3. Retro-orbital autoimmunity
4. Pathogenesis of Graves' ophthalmopathy: Recent controversies and progress
5. Thyroid-associated eye disease: Pathophysiology
6. Pathogenesis of Graves' ophthalmopathy-current understanding
7. Relationship between disease duration and predominant orbital T-cell subset in Graves' ophthalmopathy
8. T cells and fibroblasts in affected extraocular muscles in early and late thyroid associated ophthalmopathy
9. Retrobulbar T cells from patients with Graves' ophthalmopathy are CD8+ and specifically recognize autologous fibroblasts
10. Analysis of orbital T cells in thyroid-associated ophthalmopathy
11. Increased sulfatation of orbital glycosaminoglycans in Graves' ophthalmopathy
12. Management of Graves' ophthalmopathy: Reality and perspectives
13. Graves' disease
14. Graves' ophthalmopathy: Diagnosis and management
15. Octreotide
16. Current management of acromegaly
17. Somatomedin C in pathogenesis of malignant exophthalmos of endocrine origin
18. Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease
19. Somatostatin-receptor scintigraphy in Graves' orbitopathy
20. Somatostatin receptor expression and effects of octreotide in cultured retroorbital cells from patients with Graves ophthalmopathy
21. Somatostatin receptor gene expression and inhibitory effects of octreotide on primary cultures of orbital fibroblasts from Graves' ophthalmopathy
22. 1]-octreotide scintigraphy in thyroidal and orbital Graves' disease: A parameter for disease activity?
23. 111In-octreotide
24. Octreotide-scintigraphy is a disease-activity parameter in Graves' ophthalmopathy
25. The role of octreoscan in thyroid eye disease
26. Somatostatin receptor scintigraphy before and after treatment with somatostatin analogues in patients with thyroid eye disease
27. 1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy
28. Clinical implications of somatostatin-receptor scintigraphy in ophthalmic Graves' disease
29. The treatment of Graves' ophthalmopathy with synthetic somatostatin analogue (octreotide)
30. Octreotide and Graves' ophthalmopathy and pretibial myxoedema
31. Octreotide and urinary glycosaminoglycan in Graves' disease
32. Octreotide in the management of Graves' ophthalmopathy - Changes in insulin-like growth factor 1 levels do not predict clinical response
33. Somatostatin receptors in the orbits
34. Effects of octreotide treatment on Graves' ophthalmopathy and circulating sICAM-1 levels
35. The effect of somatostatin versus corticosteroid in the treatment of Graves' ophthalmopathy
36. Therapy with octreotide in patients with Graves orbitopathy who failed to respond to corticosteroid therapy
37. Effect of octreotide treatment on Graves' ophthalmopathy
38. Lanreotide in the treatment of patients with thyroid eye disease
39. Long-acting somatostatin analogues are effective in the treatment of Graves' ophthalmopathy
40. Molecular pharmacology of somatostatin receptor subtypes
41. Somatostatin analogues in the treatment of thyroid eye disease
42. Short term somatostatin infusion affects T-lymphocyte responsiveness in humans